DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,388,612 | -31.8% | 406,622 | -2.4% | 0.01% | -30.0% |
Q2 2023 | $12,299,266 | +26.0% | 416,783 | -1.6% | 0.02% | +25.0% |
Q1 2023 | $9,761,242 | -19.4% | 423,665 | -2.8% | 0.02% | -23.8% |
Q4 2022 | $12,116,066 | -10.9% | 435,673 | -1.7% | 0.02% | -12.5% |
Q3 2022 | $13,599,000 | +2.5% | 443,101 | -1.7% | 0.02% | +9.1% |
Q2 2022 | $13,264,000 | -21.3% | 450,689 | -14.0% | 0.02% | 0.0% |
Q1 2022 | $16,861,000 | -27.5% | 524,131 | +0.5% | 0.02% | -21.4% |
Q4 2021 | $23,255,000 | -16.3% | 521,408 | -5.4% | 0.03% | -17.6% |
Q3 2021 | $27,797,000 | -37.5% | 550,987 | -2.8% | 0.03% | -35.8% |
Q2 2021 | $44,463,000 | +37.6% | 566,845 | +0.2% | 0.05% | +29.3% |
Q1 2021 | $32,311,000 | -8.9% | 565,866 | +33.7% | 0.04% | -4.7% |
Q4 2020 | $35,460,000 | – | 423,353 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |